Page 1,813«..1020..1,8121,8131,8141,815..1,8201,830..»

Stem cells reverse MS: Medicine's next big thing?

Posted: March 31, 2015 at 6:50 pm

SALT LAKE CITY, Utah. (Ivanhoe Newswire) -- Multiple sclerosis is a scary and unpredictable disease. A patient's own immune system attacks the nervous system, causing numbness, dizziness, and in some cases, paralysis. But a team of researchers at the University of Utah found that human stem cells didn't just stop symptoms in animals, they reversed them.

Rachel Taylor was diagnosed with MS 14 years ago.

It was terrifying. It was like having a wet, heavy blanket put over your life. I was active, I was a runner, I was outdoors playing and over the course of a few months, I couldn't figure out why I couldn't keep up Taylor told Ivanhoe.

Rachel knew what was wrong; she'd been working with the MS society bike rides for years. Rachel's in remission now, but she is still thrilled with Tom Lane Ph.D., Professor of Pathology at the University of Utah's stem cell discovery.

Professor Lane told Ivanhoe, We have animals that are paralyzed that cannot right themselves, and once we engraft the neural stem cells into the spinal cords, within three weeks, the majority of the animals, about 80 to 85 percent, will regain motor skills.

Researchers say MS damages myelin, a layer around nerve cells. Once injected, the human neural cells stimulate the mouse's own cells to repair the damage. When nerve cell function returns, the mice can walk and run again.

Rachel says this discovery could be life-changing for many of her friends.

Researchers say after the mice regained function, their bodies rejected the stem cells, which vanished, eliminating the possibility that those cells could become tumors. Professor Lane is hoping this procedure could be ready for human clinical trials in two to three years.

Contributors to this news report include: Cyndy McGrath, Supervising Producer; Wendy Chioji, Field Producer; Cortni Spearman, Assistant Producer; Jason Ball, Videographer and Jamison Koczan, Editor.

BACKGROUND: Over the past 50 years, it has been discovered that more than two to three times as many women develop Multiple Sclerosis than men. Although there is no evidence that MS is directly inherited, genetic risk factors have been studied and were found to increase the possibility of developing the disease. Low vitamin D and smoking are considered environmental factors that can increase the risk of MS. Symptoms of MS occur when there is inflammation in the central nervous system inflammation which, in turn, damages the protective insulation of nerve fibers (myelin), the cells that make the myelin (oligodendrocytes) and sometimes the actual nerve fiber. MS does not always cause paralysis, and about two-thirds of people with MS are still able to walk, usually with the help of an aid (cane, crutches). (Source: http://www.nationalmssociety.org/What-is-MS, http://www.nationalmssociety.org/What-is-MS/MS-FAQ-s#question-Who-gets-MS)

Read the original:
Stem cells reverse MS: Medicine's next big thing?

Posted in Stem Cells | Comments Off on Stem cells reverse MS: Medicine's next big thing?

120.18 /$ (11 a.m.)

Posted: March 31, 2015 at 6:50 pm

Fujifilm Co. said Monday it will buy a U.S.-based developer of induced pluripotent stem (iPS) cells to strengthen its position in the field of regenerative medicine field, especially new drug development.

Fujifilm said the firm has agreed with Cellular Dynamics International Inc. (CDI) to buy all of its stock for $307 million, or about 36 billion, through a takeover bid.

We are taking a significant and strong step to expand our regenerative medicine business with this acquisition, Fujifilm Chairman Shigetaka Komori said at a news conference in Tokyo.

We hope to become the worlds No. 1 firm in the field of regenerative medicine, he said.

Expectations toward regenerating human tissues from stem cells have been rising in recent years with technological developments, including the use of iPS cells, which are capable of turning into any kind of tissue in the body, and 3-D bioprinters.

Fujifilm sees great potential in new drug development, as the regenerated human tissue can be used to screen new drugs and is expected to someday replace animal testing.

Fujifilm also makes a biomaterial called recombinant peptide (RCP), which is a synthetic protein, that is used to regenerate human tissue by mixing with human stem cells.

Whats more, the firm has Japan Tissue Engineering Co., which provides tissue-engineered medical products like autologous cultured cartilage within its group, so acquiring CDI will bring synergies to the group, according to Fujifilm executive Yuzo Toda.

CDI, based in Wisconsin, researches and manufactures human tissue cells derived from iPS cells, such as hepatocytes and cardiomyocytes, for pharmaceutical makers.

The firm was founded in 2004 and went public on the Nasdaq stock market in 2013 and currently has about 150 employees. It posted $16.6 million in sales in 2014 and an operating loss of $29.2 million.

Read more here:
120.18 /$ (11 a.m.)

Posted in Regenerative Medicine | Comments Off on 120.18 /$ (11 a.m.)

Stem Cell Therapy for Neuromuscular Diseases | InTechOpen

Posted: March 31, 2015 at 6:46 pm

Posted in Cell Therapy | Comments Off on Stem Cell Therapy for Neuromuscular Diseases | InTechOpen

New study: Stem cell field is infected with hype

Posted: March 31, 2015 at 6:43 pm

When billions of dollars are at stake in scientific research, researchers quickly learn that optimism sells.

A new study published inScience Translational Medicineoffersa window into how hype arises in the interaction between the media and scientific researchers, and how resistant the hype machine is to hard, cold reality. The report'sfocus is on overly optimisticreporting on potentialstem cell therapies. Its findings are discouraging.

The study by Timothy Caulfield and Kalina Kamenova of the University of Alberta law school (Caulfieldis also on the faculty at the school of public health) found that stem cell researchers often ply journalists with "unrealistic timelines" for the development of stem cell therapies, and journalists oftenswallow these claims uncritically.

The authorsmostly blame the scientists, who need to be more aware of "the importance of conveying realistic...timelines to the popular press." We wouldn't give journalists this much of a pass; writers on scientific topics should understand that the development of drugs and therapies can take years and involve myriad dry holes and dead ends. They should be vigilant againstgaudypromises.

That's especially true instem cell research, whichis slathered with so much money that immoderate predictions of success are common. The best illustration of that comes from California's stem cell program--CIRM, or the California Institute for Regenerative Medicine--a $6-billion public investment that was born in hype.

The promoters of Proposition 71, the 2004 ballot initiative that created CIRM, filled the airwaves with adsimplyingthat the only thing standing between Michael J. Fox being cured of Parkinson's or Christopher Reeve walking again was Prop 71's money. Theycommissioned a studyassertingthat California might reap a windfall in taxes,royalties and healthcare savings up to seven times the size ofits $6-billion investment. One wouldn't build a storage shed on foundations this soft, much less a $6-billion mansion.

As we've observed before, "big science" programs create incentivesto exaggerateresults to meet the public's inflated expectations. The phenomenon was recognized as long ago as the 1960s, when the distinguished physicist Alvin Weinberg warnedthat big science "thrives on publicity," resulting in "the injection of a journalistic flavor into Big Science which is fundamentally in conflict with the scientific method....The spectacular rather than the perceptive becomes the scientific standard."

Interestingly, the event used by the Alberta researchers as the fulcrum of their study has a strong connection to CIRM. It's the abrupt 2011 decision by Geron Corp.to terminate its pioneering stem cell development program. This was a big blow to the stem cell research community and to CIRM, which had endowed Geron with a $25-million loan for its stem cell-basedspinal cord therapy development. Then-CIRM Chairman Robert Klein II had called the loan a "landmark step."

There had been evidence, however, that CIRM, anxious to show progress toward bringing stem cell therapies to market, had downplayed legitimate questions about the state of Geron's science and the design of the clinical trial. AndGeron had been criticized in the past for over-promising results.

In their study, Caulfield and Kamenova examined more than 300 articles appearing in 14 general-interest newspapers in the U.S., Canada, and Britain from 2010 to2013. They scrutinizedthe articles' reporting oftimelines for the "realization of the clinical promise of stem cell research" and their perspective on the future of the field generally. The U.S. newspapers were the New York Times, Wall Street Journal, Washington Post, and USA Today.

See more here:
New study: Stem cell field is infected with hype

Posted in Cell Therapy | Comments Off on New study: Stem cell field is infected with hype

Sight Restoration Through Stem Cell Therapy – Subject of June Symposium of Experts

Posted: March 31, 2015 at 6:43 pm

Los Angeles, CA (PRWEB) March 31, 2015

This June 13th, a distinguished group of Ph.Ds, M.Ds and Professors from the top U.S and International Medical Schools will come together in Santa Monica, California, to share their latest research on the application of stem cell therapy in treatments and cures for blinding eye diseases. The symposium is organized and funded by the Ocular Research Symposia Foundation, Inc. (ORSF), an independent nonprofit that has been convening intimate meetings of top experts in the field of eye research since 2002 to move the research discussed forward at an accelerated pace.

Gerald J. Chader, Ph.D., Executive Director of the Ocular Stem Cell Project in the Department of Ophthalmology at the University of Southern California, and Dr. Michael Young of Harvard Medical School are co-chairs of this year's symposium. "ORSF has the unique ability to bring together experts in the key foundational issues of stem cell research, as well as a range of clinical applications," states Dr. Chader. "Beyond the academic presentations on stem cell therapy relating to glaucoma, corneal diseases, macular degeneration and other incurable eye diseases, the participants will devote time to discussing strategies to move the most promising research forward toward clinical trials and effective treatments and cures. Our approach is unique. We believe we can accomplish more in a few hours of frank discussions among colleagues than can be achieved in a week-long conference of hundreds of attendees."

After each symposium, ORSF produces a comprehensive report bringing together the many discussions and findings from the latest meeting. In 2013, their report on "The Aging Eye" was published as a special issue of "IOVS: Investigative Ophthalmology & Visual Science," the Journal of the Association for Research in Vision and Ophthalmology. They will also be publishing this year's report. The reports offer a prime vehicle for spreading information beyond the symposium participants themselves to other researchers, clinicians,corporations, medical schools, government entities and the interested public. The reports are available free of charge through the ORSF web site.

ABOUT OCULAR RESEARCH SYMPOSIA FOUNDATION, INC.

The Ocular Research Symposia Foundation emerged from the Drabkin Research Symposia, held from 2002 to 2011. Founded by Robert Drabkin, the early symposia were presented biennially through The Washington Advisory Group. When this advisory group disbanded, ORSF was incorporated in California with ongoing support from the Drabkin Foundation, continuing the catalytic role of the symposia breaking down academic silos and making the exchange of critical information possible. Tax deductible donations to the organization go toward programming future meetings, inviting experts to the symposia, publishing reports, and spreading information throughout the ocular research field. This month, the Foundation was pleased to receive a small peer review grant for this symposium from the California Institute of Regenerative Medicine.

View post:
Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts

Posted in Stem Cell Therapy | Comments Off on Sight Restoration Through Stem Cell Therapy – Subject of June Symposium of Experts

Cord Blood Banking with GeneCell – Video

Posted: March 30, 2015 at 10:52 pm


Cord Blood Banking with GeneCell
Learn the process of Cord Blood Banking with GeneCell and get the peace of mind you deserve. Cord blood contains stem cells that can be transfused to a patient to treat various diseases,...

By: genecellintl

Read the original here:
Cord Blood Banking with GeneCell - Video

Posted in Stem Cell Videos | Comments Off on Cord Blood Banking with GeneCell – Video

Stem cell firm Cellular Dynamics being acquired by Japanese company for $307 million

Posted: March 30, 2015 at 4:44 pm

Madison-based stem cell company Cellular Dynamics InternationalInc. is being acquired by Tokyo-based Fujifilm Holdings Corp., the companies announced in a news release Monday.

The deal was described as "an all-cash tender offer to be followed by a second step merger," with Fujifilm buying all shares of CDI stock for $16.50 per share, valuing the deal at about $307 million.

The offer is a premium of 108 percent to CDI's closing stock price on Friday.

The news sent the stock shooting up in the range of $16.40 to $16.52 a share in morning trading, with more than 2 million shares changing hands by noon, compared with an average volume of 69,000 a day, over the past three months.

When the deal is completed, CDI will continue to run its operations in Madison and Novato, California as a consolidated subsidiary of Fujifilm. CDI had 155 employees at the end of 2014.

The deal, which is expected to close during the second quarter, has been approved by the boards of both companies.

"CDI has become a leader in the development and manufacture of fully functioning human cells in industrial quantities to precise specifications,"Robert J. Palay, Chairman and CEO of CDI, said in the release. "CDI and Fujifilm share a common strategic vision for achieving leadership in the field of regenerative medicine. The combination of CDI's technology with Fujifilm's technologies, know-how, and resources brings us ever closer to realizing the promise of discovering better, safer medicines and developing new cell therapies based on iPSCs."

CDI was founded in 2004 and listed on the NASDAQ stock exchange in July 2013. The company had global revenues of $16.7 million in the year ended Dec. 31, 2014.

Fujifilm has successfully transformed its business structure for growth by expanding from traditional photographic film to other priority business fields. Positioning the healthcare business as one of its key growth areas, Fujifilm is seeking to cover "prevention, diagnosis, and treatment" comprehensively.

CDI's technology platform enables the production of high-quality fully functioning human cells, including induced pluripotent stem cells (iPSCs), on an industrial scale. Customers use CDI's products, among other purposes, for drug discovery and screening, to test the safety and efficacy of their small molecule and biological drug candidates, for stem cell banking, and in the research and development of cellular therapeutics. CDI's proprietary iCell product catalogue encompasses 12 different iPSC based cell types, including iCell Cardomyocytes, iCell Hepatocytes, and iCell Neurons. During 2014 CDI sold to 18 of 20 top biopharmaceutical companies.

Read the original here:
Stem cell firm Cellular Dynamics being acquired by Japanese company for $307 million

Posted in Cell Medicine | Comments Off on Stem cell firm Cellular Dynamics being acquired by Japanese company for $307 million

Research develops mini-lung structures

Posted: March 30, 2015 at 9:46 am

Stem cell research has long been seen as a new frontier for disease therapeutics. By coaxing stem cells to form 3D miniature lung structures, University researchers are helping explain why.

In a collaborative study, University researchers devised a system to generate self-organizing human lung organoids, or artificially-grown organisms. These organoids are 3D models that can be used to better understand lung diseases.

Jason Spence, the assistant professor of internal medicine and cell and developmental biology, who was a senior author of the study, said one of the key implications of these lungs is the controlled environment they offer for future research.

These mini lungs will allow us to study diseases in a controlled environment and to develop and test new drugs, he said.

Specifically, Spence said, scientists will be able to take skin samples from patients with a particular form of a lung disease, reprogram the cells into stem cells and then generate lung tissue for further study. He said by analyzing the disease in a controlled environment, researchers can gain insight into the progression of various diseases and then tailor drugs for treatment.

Rackham student Briana Dye was also a lead author of the study. She said the team manipulated numerous signaling pathways involved with cell growth and organ formation to make the miniature lungs.

First, Dye said the scientists used proteins called growth factors to differentiate embryonic stem cells into endoderm, the germ layer that gives rise to the lungs. Different growth factors were then used to cause the endoderm to become lung tissue.

We add specific growth factors, proteins that turn on pathways in the cells, that will then cause them to lift off the monolayer so that we have this 3D spherical tissue, she said.

Previous research has used stem cells in a similar manner to generate brain, intestine, stomach and liver tissue. Dye said one of the advantages of stem cell research is its direct path to studying human tissue.

We have worked with many animal models in the past, Dye said. Animal models present obstacles because they dont exactly behave the way human tissue and cells do. This is why stem cells are so promising.

Continue reading here:
Research develops mini-lung structures

Posted in Stem Cells | Comments Off on Research develops mini-lung structures

Ask Dr. Lemper | Stem Cell Therapy Treatments – Video

Posted: March 30, 2015 at 9:40 am


Ask Dr. Lemper | Stem Cell Therapy Treatments
Facebook https://www.facebook.com/lemperpaincenters Submit a question https://bit.ly/askdrlemper Continuing #39;Ask Dr Lemper #39;, Dr. Lemper answers the following question: Do you think...

By: Dr. Brian Lemper, D.O.

Read this article:
Ask Dr. Lemper | Stem Cell Therapy Treatments - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Ask Dr. Lemper | Stem Cell Therapy Treatments – Video

Stem Cell Grants for Spina Bifida and Diabetic Wound Treatments

Posted: March 30, 2015 at 9:40 am

(SACRAMENTO, Calif.) - The state stem cell agency, California Institute for Regenerative Medicine (CIRM),awarded a pair of grants totaling more than $7 million to UC Davis School of Medicine researchers who are working to develop stem cell therapies for spina bifida and chronic diabetic wounds. The funding is part of what the agency considers "the most promising" research leading up to human clinical trials using stem cells to treat disease and injury. Diana Farmer, professor and chair of surgery at UC Davis Medical Center, is developing a placental stem cell therapy for spina bifida, the common and devastating birth defect that causes lifelong paralysis as well as bladder and bowel incontinence. She and her team are working on a unique treatment that can be applied in utero - before a baby is born -- in order to reverse spinal cord damage. Roslyn Rivkah Isseroff, a UC Davis professor of dermatology, and Jan Nolta, professor of internal medicine and director of the university's Stem Cell Program, are developing a wound dressing containing stem cells that could be applied to chronic wounds and be a catalyst for rapid healing. This is Isseroff's second CIRM grant, and it will help move her research closer to having a product approved by the U.S. Food and Drug Administration that specifically targets diabetic foot ulcers, a condition affecting more than 6 million people in the country. The CIRM board, which met in Berkeley today, has high hopes for these types of research that the agency funded in this latest round of stem cell grants. "This investment will let us further test the early promise shown by these projects," said Jonathan Thomas, chair of CIRM's governing board. "Preclinical work is vital in examining the feasibility, potential effectiveness and safety of a therapy before we try it on people. These projects all showed compelling evidence that they could be tremendously beneficial to patients. We want to help them build on that earlier research and move the projects to the next level." The CIRM grants are designed to enable the UC Davis research teams to transition from preclinical research to preclinical development over the next 30 months to be able to meet the FDA's rigorous safety and efficacy standards for Investigative New Drugs. As the former surgeon-in-chief at UCSF Benioff Children's Hospital, Farmer helped pioneer fetal surgery techniques for treating spina bifida before birth. The condition, also known as myelomeningocele, is one of the most common and devastating birth defects worldwide, causing lifelong paralysis as well as bowel and bladder incontinence in newborns. Farmer has been investigating different stem cell types and the best way to deliver stem cell-based treatments in the womb for the past six years. She and her research colleagues recently discovered a placental therapy using stem cells that cures spina bifida in animal models. That discovery requires additional testing and FDA approval before the therapy can be used in humans. With the CIRM funding, Farmer and her team plan to optimize their stem cell product, validate its effectiveness, determine the optimal dose and confirm its preliminary safety in preparation for human clinical trials. Isseroff, who also serves as chief of dermatology and director of wound healing services for the VA Northern California Health Care System, has long been frustrated by the challenges of treating the chronic, non-healing wounds of diabetics. In 2010, she and Nolta received a CIRM grant to begin developing a bioengineered product for treating chronic diabetic wounds. Foot ulcers, in particular, affect about 25 percent of all diabetic patients and are responsible for most lower-limb amputations. Isseroff and her research team created a treatment using stem cells derived from bone marrow (mesenchymal stem cells) along with a FDA-approved scaffold to help regenerate dermal tissue and restart the healing process. Their studies found the technique to be highly effective for healing wounds in animal models. With this latest CIRM grant, Isseroff's team will refine their therapeutic technique by determining the safest dosage for regenerating tissue and testing their product in skin-wound models that closely resemble those in diabetic humans. Nolta also plans to create a Master Cell Bank of pure and effective human mesenchymal stem cells, and establish standard operating procedures for use in diabetic wound repair. The results of their efforts will enable UC Davis to move closer to FDA approval for human clinical trials in the next two and a half years. "These amazing research efforts are giant steps forward in turning stem cells into cures," said Nolta, who also directs the UC Davis Institute for Regenerative Cures in Sacramento. "This preclinical research is the most crucial, and often the toughest, stage before we move scientific discoveries from the laboratory bench to the patient's bedside. We are now poised as never before to make a big difference in the lives of people with spina bifida and non-healing diabetic wounds." For more information, visit UC Davis School of Medicine at http://medschool.ucdavis.edu.

Originally posted here:
Stem Cell Grants for Spina Bifida and Diabetic Wound Treatments

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Stem Cell Grants for Spina Bifida and Diabetic Wound Treatments

Page 1,813«..1020..1,8121,8131,8141,815..1,8201,830..»